Brexit could impact on patients and pharmaceutical manufacutuers

Angus MP Mike Weir has expressed concern that UK patients will not have to wait up to a year for access to new drugs as a result of Brexit. There could also be an impact on drug manufacturers such as GSK.

The European Medicine Agency (EMA) provides a drug licensing system which covers the 500 million people in the EEA, meaning new drugs are licensed in the UK six to 12 months before markets such as Canada and Australia. The UK government have indicated that the UK will not seek to remain a member of EMA as any part of a Brexit deal.

Commenting Mr Weir said “The European Medicine Agency provides a single drug licensing system for over 500 million people in the EEA which means new drugs are licensed in the UK around six to 12 months ahead of countries like Canada and Australia.

“The system also means that manufacturers, such as GSK, only need to get any new drug licensed once rather than going through 28 national agencies.”

“Leaving the EMA would have an impact on the UK Pharmaceutical industry as well as denying patients early access to innovative medicines.”

“Clearly drugs require to be licensed before they can be used and delays could adversely impact on patients.”

Ends